‘Life saving’ drug for people with opioid dependency to be pulled from Australia by end of year
Pharmaceutical company Indivior is withdrawing the opioid dependency drug Sublocade from the Australian market by the end of the year. The decision follows a trend of companies citing commercial viability concerns amid shifting global drug pricing policies.
Why it matters
The withdrawal of a subsidized, life-saving medication creates significant health risks for patients and highlights the impact of international policy changes on local healthcare access.
The marketing and sale of the long-acting injectable prescription opioid, Sublocade, will end in Australia from 31 December, US pharmaceutical company Indivior has confirmed. Photograph: Chicago Tribune/TNS The marketing and sale of the long-acting injectable prescription opioid, Sublocade, will end in Australia from 31 December, US pharmaceutical company Indivior has confirmed. Photograph: Chicago Tribune/TNS Health ‘Life-saving’ drug for people with opioid dependency to be pulled from Australia by end of year Exclusive: Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administration
The article reports on a corporate decision and its potential health consequences without taking a political stance, though it notes the context of US policy changes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in